Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved, usual_care.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Dapagliflozin 10 mg

Core clinician-reference fields are available or not applicable.

Patients received a fixed-dose combination of dapagliflozin and gliclazide for 16 weeks.

FDC of Dapagliflozin 10 mg + Gliclazide SR 60 mg

Patients in the test arm received FDC of dapagliflozin 10 mg and gliclazide 60 mg SR tablets, while those in the reference arm received dapagliflozin 10 mg, given orally every day for 16 weeks of the treatment period.

Patients received dapagliflozin 10 mg monotherapy for 16 weeks.

Patients in the reference arm received dapagliflozin 10 mg, given orally every day for 16 weeks of the treatment period.

Dapagliflozin and Gliclazide Combination Improves Glycemic Control

Not extracted from the authoritative source.

Not applicable to this study design or comparison.

Source evidence could not be resolved sufficiently for this field.

Clinician-reference record is usable with limitations in: design, arms, risk_of_bias.

Authoritative quality diagnostic: source evidence unresolved.

Dapagliflozin-linagliptin combo improves glycemic control and organ protection

Loose combination (LC) arm

Participants received one tablet containing dapagliflozin 10 mg and pioglitazone 15 mg, administered orally once daily in the morning.

Fixed-dose combination (FDC) arm

Participants were randomized in a 1:1 ratio to receive one of the two study treatments for 12 weeks, in addition to their background metformin regimen. FDC arm One tablet containing dapagliflozin 10 mg and pioglitazone 15 mg, administered orally once daily in the morning.

Participants received the same agents administered separately as an add-on therapy to stable metformin.

Participants were randomized in a 1:1 ratio to receive one of the two study treatments for 12 weeks, in addition to their background metformin regimen. LC arm: same agents administered separately.

Dapagliflozin-pioglitazone combo improves glycemic control in type 2 diabetes

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 2 studies described adult participants.

1 of 2 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Structured population data were available for 3 of 3 supporting studies. 1 study described adult participants.

2 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Upstream consistency scoring indicates mixed findings across the evidence.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, usual_care.

2 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

3 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 2 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved.

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 1 studies with type 1 diabetes, 1 studies with type 2 diabetes. 3 studies described adult participants.

Structured population data were available for 4 of 4 supporting studies. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: other, usual_care.

3 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 4 of 4 supporting studies. 4 studies described participants with type 2 diabetes. 4 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 3 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.

Evidence uses heterogeneous comparison contexts: placebo, unknown_unresolved, usual_care.

Structured population data were available for 6 of 6 supporting studies. Diabetes type was heterogeneous: 1 studies with type 1 diabetes, 1 studies with type 2 diabetes. 3 studies described adult participants.

3 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, unknown_unresolved, usual_care.

3 of 6 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. 2 studies described participants with type 2 diabetes. 4 studies described adult participants.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, unknown_unresolved.

2 of 4 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 3 studies described adult participants.

4 of 4 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 7 of 7 supporting studies. Diabetes type was heterogeneous: 4 studies with type 2 diabetes, 1 studies with type 1 diabetes. 5 studies described adult participants.

3 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo, unknown_unresolved, usual_care.

2 studies contain conflicting p-value and significance fields; those significance claims are suppressed.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

Structured population data were available for 9 of 9 supporting studies. Diabetes type was heterogeneous: 4 studies with type 1 diabetes, 2 studies with type 2 diabetes. 7 studies described adult participants.

Dapagliflozin × Fasting Plasma Glucose (FPG)

Available supporting studies

Dapagliflozin and Gliclazide Combination Improves Glycemic Control

Dapagliflozin-linagliptin combo improves glycemic control and organ protection

Dapagliflozin-pioglitazone combo improves glycemic control in type 2 diabetes